Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Histalim

Histalim
2005 FOUNDED
M&A STATUS
31-40 EMPLOYEES
Buyout/LBO LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Provider of histology, immunohistochemistry (IHC), In Situ Hybridization (ISH) and image analysis services. The company is engaged in development of new therapies in the domains of oncology and chronic diseases, including therapeutic antibody and new generation diagnostic tools. It also takes part in development projects for pharmaceutic products, medical devices and diagnostic tools.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Private Equity-Backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Parent Company
Primary Office
  • 126 Rue Emile Baudot
  • 34000 Montpellier
  • France

+33 04 00 00 00 00

Histalim Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Histalim‘s full profile, request access.

Request full access to PitchBook

Histalim Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Empire Genomics Venture Capital-Backed Buffalo, NY 00.000 0000000000 0 00.000
00000000 0000 Corporation Boulder, CO
0000000 0000 00000 Corporate Backed or Acquired Maryland Heights, MO 000000&0
To view this company’s complete list of competitors, request access »

Histalim Executive Team (1)

Name Title Board
Seat
Contact
Info
Jean-Philippe Coton Managing Director & Publication Manager